kras_g12c_in_nsclc A confirmatory Phase 3, a full approval, and a first-line combo that just crossed 45% ORR. Here's what changed this week.
post-osimertinib MARIPOSA-2 hardens, C797S overtakes MET as the #1 on-target driver, and subcutaneous amivantamab drops infusion time under five minutes.
mrd_in_resected_nsclc A sponsored deep dive on how ctDNA MRD is reshaping adjuvant decisions.
destiny-lung DESTINY-Lung02 rewrote the label, WCLC halved the real-world ILD rate, and the CNS data quietly repositioned T-DXd as a brain-active option.
perioperative_io CheckMate 77T reads out at 3 years, KEYNOTE-671 hardens OS, and a Phase 2 quietly asks whether ctDNA can spare a third of patients from adjuvant IO.
bispecifics_after_osi A sponsored look at where EGFR × MET bispecifics fit after osimertinib progression.
c797s_frontier A quiet WCLC signal became the loudest story in EGFR resistance. C797S has overtaken MET as the #1 on-target driver, and it's already reshaping fourth-gen TKI programs.
trop2_adcs TROPION-Lung01, EVOKE-01, and a full FDA approval for Dato-DXd. The ADC wave that hit HER2+ is now landing on the un-selected non-squamous population.
sclc's_big_year DeLLphi-301 confirms a real OS win, IMforte hardens maintenance, and community sites are figuring out how to safely deliver a BiTE without a hospital bed.
brain_mets,_rewired For oncogene-driven NSCLC and increasingly for IO-eligible disease, drug is coming before radiation. The SRS-first reflex is quietly losing ground.